Emboldened by a positive PhIII, Novartis steers a late-stage BTK inhibitor into a pivotal MS trial

John Carroll

Editor & Founder

Novartis is taking a digital turn at the upcoming ECTRIMS conference with dozens of abstracts on its immunology drugs already on the market. And notably …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Emboldened by a positive PhIII, Novartis steers a late-stage BTK inhibitor into a pivotal MS trial

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

CBER's deputy director departs as staff shakeup continues

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

Medicare spending on common diabetes drugs skyrocketed, HHS inspector general finds

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

How AI can address ongoing challenges in the life sciences industry

Em­bold­ened by a pos­i­tive PhI­II, No­var­tis steers a late-stage BTK in­hibitor in­to a piv­otal MS tri­al

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Emboldened by a positive PhIII, Novartis steers a late-stage BTK inhibitor into a pivotal MS trial